Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the hematological responses based on the response assessment criteria defined in
this study (the 531-004 response assessment criteria) when AMG531 is subcutaneously
(SC)-administered with ciclosporin A (CsA) therapy for 6 months in patients with aplastic
anemia (AA) who were previously untreated with immunosuppressive therapy.